Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection

Creative Commons License

Venkatesan S., Myles P. R., Bolton K. J., Muthuri S. G., Al Khuwaitir T., Anovadiya A. P., ...More

JOURNAL OF INFECTIOUS DISEASES, vol.221, no.3, pp.356-366, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 221 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.1093/infdis/jiz152
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, CINAHL, EMBASE, Environment Index, MEDLINE, Public Affairs Index, Veterinary Science Database
  • Page Numbers: pp.356-366
  • Keywords: Neuraminidase inhibitors, pandemic influenza, IPD meta-analysis, length of stay, antivirals, OSELTAMIVIR TREATMENT, CLINICAL-FEATURES, CHILDREN, OUTCOMES, ADULTS, COMPLICATIONS, RESISTANCE, IMPACT, COHORT, RISK
  • Hacettepe University Affiliated: Yes


Background. The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear.